Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine and budesonide effects on GATA-3, RORγt, and FOXP3 in allergic rhinitis
IRCT2017042433622N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research and Technology
- Start
- May 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of fexofenadine and budesonide in allergic rhinitis (AR), sponsored by Vice Chancellor for Research and Technology. Primary endpoints: Change in GATA-3 level, Change in RORγt level and 1 more. Started May 2017; status: completed.
02
Drugs
fexofenadinebudesonide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on IRCT2017042433622N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017042433622N1.